Table 1.
Clinicopathologic characteristics of the patients
| Characteristic | Number | % |
|---|---|---|
| Total patients | 196 | |
| Median age (range) | 57 (26 to 76) | |
| <65 | 147 | 75.0 |
| ≥65 | 49 | 25.0 |
| Sex | ||
| Male | 112 | 57.1 |
| Female | 84 | 42.9 |
| Tumor location | ||
| Right | 52 | 26.5 |
| Transverse | 8 | 4.1 |
| Descending | 17 | 8.7 |
| Sigmoid and rectosigmoid | 119 | 60.7 |
| Histologic appearance | ||
| Well differentiated | 6 | 3.1 |
| Moderately differentiated | 174 | 88.8 |
| Poorly differentiated | 10 | 5.1 |
| Signet ring cell | 1 | 0.5 |
| Mucinous cell | 5 | 2.5 |
| Lymphovascular invasion (+) | 106 | 54.1 |
| Neural invasion (+) | 89 | 45.4 |
| T stage | ||
| T1 | 1 | 0.5 |
| T2 | 5 | 2.5 |
| T3 | 174 | 88.8 |
| T4 | 16 | 8.2 |
| N stage | ||
| N0 | 38 | 19.4 |
| N1 | 86 | 43.9 |
| N2 | 72 | 36.7 |
| WBC | ||
| <4,000 × 106/L | 3 | 1.5 |
| 4,000 ~ 10,000 × 106/L | 169 | 86.2 |
| >10,000 × 106/L | 24 | 12.3 |
| Hemoglobin (Hgb) | ||
| Female <12 g/dL (anemia) | 50 | 25.5 |
| Female ≥12 g/dL (normal) | 34 | 17.3 |
| Male <14 g/dL (anemia) | 66 | 33.7 |
| Male ≥14 g/dL (normal) | 46 | 23.5 |
| Platelet (PLT) | ||
| <140 × 109/L (thrombocytopenia) | 4 | 2.0 |
| 140 ~ 440 × 109/L | 185 | 94.4 |
| >440 × 109/L | 7 | 3.6 |
| Albumin | ||
| <3.8 g/dL | 40 | 20.4 |
| 3.8 ~ 5.3 g/dL | 156 | 79.6 |
| Lactate dehydrogenase (LDH) | ||
| 129 ~ 240 U/L | 41 | 20.9 |
| >240 U/L | 155 | 79.1 |
| Total bilirubin | ||
| 0.2 ~ 1.0 mg/dL | 189 | 96.4 |
| >1.0 mg/dL | 7 | 3.6 |
| Aspartate aminotransferase (AST) | ||
| 10 ~ 33 U/L | 174 | 88.8 |
| >33 U/L | 22 | 11.2 |
| Alanine aminotransferase (ALT) | ||
| 4 ~ 50 U/L | 183 | 93.4 |
| >50 U/L | 13 | 6.6 |
| Protein | ||
| <6.7 g/dL | 29 | 14.8 |
| 6.7 ~ 8.3 g/dL | 165 | 84.2 |
| >8.3 g/dL | 2 | 1.0 |
| Prognostic model (T4, Hgb) | ||
| Low-risk group | 43 | 21.9 |
| Intermediate-risk group | 139 | 70.9 |
| High-risk group | 14 | 7.2 |
| Preoperative CEA | ||
| ≤5 ng/mL | 114 | 58.2 |
| >5 ng/mL | 82 | 41.8 |
| Postoperative CEA | ||
| ≤5 ng/mL | 160 | 81.6 |
| >5 ng/mL | 36 | 18.4 |
| Side effect | ||
| Neutropenia | 154 | 78.6 |
| Gastrointestinal symptoms | 36 | 18.4 |
| Peripheral neuropathy | 40 | 20.4 |
CEA, carcinoembryonic antigen; WBC, white blood cell.